Australian (ASX) Stock Market Forum

Coronavirus (COVID-19/SARS-CoV-2) outbreak discussion

Will the "Corona Virus" turn into a worldwide epidemic or fizzle out?

  • Yes

    Votes: 37 49.3%

  • No

    Votes: 9 12.0%

  • Bigger than SARS, but not worldwide epidemic (Black Death/bubonic plague)

    Votes: 25 33.3%

  • Undecided

    Votes: 4 5.3%
  • Total voters
    75
Jump to new
I think I caught it again. Fever, then Gastro for a few days. The type of gastro where every fart is a shart kinda deal. Talk about a new wave cleanse. I almost turned inside out.
2 days of symptoms
Probably 5 days till back to ok.
 
moXJO said:
I think I caught it again. Fever, then Gastro for a few days. The type of gastro where every fart is a shart kinda deal. Talk about a new wave cleanse. I almost turned inside out.
2 days of symptoms
Probably 5 days till back to ok.
Click to expand...
Drat ! seems to be doing that, a few celebs have been in the news with recurring Covid.

I have read that it is best to take 'whatever you are taking for it" for at least two weeks after you get well.

Hopefully you win the battle a bit quicker this time
 
macca said:
Drat ! seems to be doing that, a few celebs have been in the news with recurring Covid.

I have read that it is best to take 'whatever you are taking for it" for at least two weeks after you get well.

Hopefully you win the battle a bit quicker this time
Click to expand...
It's gone and passed. Wasn't that bad really.
 



​

​

Mortality in children from influenza and respiratory syncytial virus​


From March 2020 to February 2021, UK data suggested that for those aged <18, the absolute mortality risk from SARS-CoV-2 infection was 2 per 1,000,000 infections, which is to say that those aged <18 incurred a 0.0002% chance of death from SARS-CoV-2 infection.

To put these figures into their proper context, consider the following:

“Average winter respiratory deaths attributed to influenza in children 1 month–14 years were 22 and to RSV [respiratory syncytial virus] 28; and all cause deaths to influenza 78 and to RSV 79. All cause RSV attributed deaths in infants 1–12 months exceeded those for influenza every year except 1989/90; ... Corresponding rates for children 1–4 years were 0.9 and 0.8 [per 100,000] and for older children all rates were 0.2 or less, except for an influenza rate of 0.4 in children 10–14 years.”

Therefore, more children in England between 1 month and 14 years of age died either of influenza or respiratory syncytial virus over two winters than did children <16 of COVID-19 in all of the UK during the alpha and delta waves:
  • 78 (influenza) > 44 (COVID-19)
  • 79 (RSV) > 44 (COVID-19)

For young people, infection by SARS-CoV-2 could be even less deadly than infection by influenza or RSV.



.​
 
moXJO said:
'LA times' is a bit of a bake sale.
Click to expand...
4192A5D4-B2BA-4719-B1D4-356E933D2A40.png
 
We have now passed the 5 million cases mark, a tad under 20% of the population.
At the current rate, of 350 to 400k per week, we should reach 50% of folks having a case by September.
So at what point is the pop of OZ considered to have developed herd immunity??
Mick
 
mullokintyre said:
We have now passed the 5 million cases mark, a tad under 20% of the population.
At the current rate, of 350 to 400k per week, we should reach 50% of folks having a case by September.
So at what point is the pop of OZ considered to have developed herd immunity??
Mick
Click to expand...
If the official count is 5 mil then you can at least double that, around here people between 18-30 years just let it rip.

Sick ? stay home in bed until the weekend then go for it.............

Neighbour nurse said all her kids (18, 21) friends have had it, my grandkids and their friends and flat mates (21-25)all had it.

In Argyle House, Newcastle 2 positive people gave it to 250 people in 4 hours so imagine what 12 sick people can do over a weekend when they go out Friday and Saturday nights while positive.

Probably a good thing actually, they have all had it so should not give it anyone to infect when new variant comes around.
 

​

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching​



Abstract​


Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.​
​
Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).​
​
Results: Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).​
​
Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.​


 
Top